Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Regan

Showing results (21-30 of 30) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 30 results.
Bioorganic & Medicinal Chemistry Letters|August 28, 2003
The kinetics of binding to p38MAP kinase by analogues of BIRB 796John Regan, Christopher A Pargellis, Pier F Cirillo, et al.
Journal of Medicinal Chemistry|October 17, 2003
Thermal denaturation: a method to rank slow binding, high-affinity P38alpha MAP kinase inhibitorsRachel R Kroe, John Regan, Al Proto, et al.
BMC Geriatrics|November 29, 2023
Reducing fear and avoidance of memory loss improves mood and social engagement in community-based older adults: a randomized trialFrancesca R Farina, John Regan, Melissa Marquez, et al.
The Medical Journal of Australia|August 12, 2016
Contemporary type 1 diabetes pregnancy outcomes: impact of obesity and glycaemic controlSally K Abell, Jacqueline A Boyle, Barbora de Courten, et al.
Nature Structural Biology|March 16, 2002
Inhibition of p38 MAP kinase by utilizing a novel allosteric binding siteChristopher Pargellis, Liang Tong, Laurie Churchill, et al.
Journal of Medicinal Chemistry|June 28, 2002
Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidateJohn Regan, Steffen Breitfelder, Pier Cirillo, et al.
Journal of Medicinal Chemistry|October 17, 2003
Structure-activity relationships of the p38alpha MAP kinase inhibitor 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naph- thalen-1-yl]urea (BIRB 796)John Regan, Alison Capolino, Pier F Cirillo, et al.
Bioorganic & Medicinal Chemistry Letters|June 15, 2007
New modifications to the area of pyrazole-naphthyl urea based p38 MAP kinase inhibitors that bind to the adenine/ATP siteNeil Moss, Steffen Breitfelder, Raj Betageri, et al.
Journal of Medicinal Chemistry|December 22, 2006
Quinol-4-ones as steroid A-ring mimetics in nonsteroidal dissociated glucocorticoid agonistsJohn Regan, Thomas W Lee, Renée M Zindell, et al.
Bioorganic & Medicinal Chemistry Letters|October 4, 2011
Non-steroidal dissociated glucocorticoid agonists: indoles as A-ring mimetics and function-regulating pharmacophoresRaj Betageri, Thomas Gilmore, Daniel Kuzmich, et al.
Pageof 3

Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Bioorganic & Medicinal Chemistry Letters|August 28, 2003
The kinetics of binding to p38MAP kinase by analogues of BIRB 796John Regan, Christopher A Pargellis, Pier F Cirillo, et al.
Journal of Medicinal Chemistry|October 17, 2003
Thermal denaturation: a method to rank slow binding, high-affinity P38alpha MAP kinase inhibitorsRachel R Kroe, John Regan, Al Proto, et al.
BMC Geriatrics|November 29, 2023
Reducing fear and avoidance of memory loss improves mood and social engagement in community-based older adults: a randomized trialFrancesca R Farina, John Regan, Melissa Marquez, et al.
The Medical Journal of Australia|August 12, 2016
Contemporary type 1 diabetes pregnancy outcomes: impact of obesity and glycaemic controlSally K Abell, Jacqueline A Boyle, Barbora de Courten, et al.
Nature Structural Biology|March 16, 2002
Inhibition of p38 MAP kinase by utilizing a novel allosteric binding siteChristopher Pargellis, Liang Tong, Laurie Churchill, et al.
Journal of Medicinal Chemistry|June 28, 2002
Pyrazole urea-based inhibitors of p38 MAP kinase: from lead compound to clinical candidateJohn Regan, Steffen Breitfelder, Pier Cirillo, et al.
Journal of Medicinal Chemistry|October 17, 2003
Structure-activity relationships of the p38alpha MAP kinase inhibitor 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)naph- thalen-1-yl]urea (BIRB 796)John Regan, Alison Capolino, Pier F Cirillo, et al.
Bioorganic & Medicinal Chemistry Letters|June 15, 2007
New modifications to the area of pyrazole-naphthyl urea based p38 MAP kinase inhibitors that bind to the adenine/ATP siteNeil Moss, Steffen Breitfelder, Raj Betageri, et al.
Journal of Medicinal Chemistry|December 22, 2006
Quinol-4-ones as steroid A-ring mimetics in nonsteroidal dissociated glucocorticoid agonistsJohn Regan, Thomas W Lee, Renée M Zindell, et al.
Bioorganic & Medicinal Chemistry Letters|October 4, 2011
Non-steroidal dissociated glucocorticoid agonists: indoles as A-ring mimetics and function-regulating pharmacophoresRaj Betageri, Thomas Gilmore, Daniel Kuzmich, et al.
Pageof 3